Kintsugi Fails to Get FDA Approval for Its AI

⚡

Key Takeaways

1The startup Kintsugi has developed an AI to detect depression from speech, but did not receive FDA approval.

2After this setback, Kintsugi is shutting down and making its technology available as open-source for other uses.

3Kintsugi's AI could be repurposed to detect audio deepfakes, broadening its application.

💡Why it matters — Kintsugi's failure highlights the regulatory challenges for innovations in mental health, hindering the adoption of new technologies.

⚡Le brief IA que lisent les pros

Le brief IA que les pros lisent chaque soir

Les 7 actus IA du jour, décryptées en 5 min. Gratuit.

Inclus dès l'inscription : notre sélection des meilleurs guides & comparatifs IA.

Choisis ton rythme

Gratuit · Pas de spam · Désabonnement en 1 clic

📄

Full Analysis

For seven years, the California startup Kintsugi has focused on developing an artificial intelligence capable of detecting signs of depression and anxiety from speech. However, the company recently announced its closure after failing to obtain timely approval from the Food and Drug Administration (FDA) for its technology.

As a result, Kintsugi has decided to make most of its technology available as open-source. This decision paves the way for new potential applications, including in the field of audio deepfake detection, beyond the healthcare sector.

Currently, mental health assessments primarily rely on questionnaires and clinical interviews, unlike the laboratory tests commonly used in physical medicine. Kintsugi's software stood out for its unique approach, analyzing not the content of speech but the manner in which it is delivered.

⚡

Brief IA — L'actualité IA en français

L'essentiel de l'actualité de l'intelligence artificielle, décrypté et expliqué chaque jour.

📰 Voir toutes les actus IA →